Member access

4-Traders Homepage  >  Shares  >  Amex  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Amex
10/16/2014 10/17/2014 10/20/2014 10/21/2014 10/22/2014 Date
2.61(c) 2.65(c) 2.44(c) 2.36(c) 2.3 Last
914 949 1 507 043 663 578 349 216 244 537 Volume
+8.30% +1.53% -7.92% -3.28% -2.54% Change
More quotes
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
Surperformance© rating of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More about the company
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 38,2 M
EBIT 2014 -12,0 M
Net income 2014 -1,28 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 14,0x
Capi. / Sales 2014 5,78x
Capitalization 221 M
More Financials
Latest news on PROTALIX BIOTHERAPEUTICS I
09/29 PROTALIX BIOTHERAPEUTICS : Change in Directors or Principal Officers, Financial ..
09/29 Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executiv..
09/04 PFIZER : and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indicat..
09/04 PROTALIX BIOTHERAPEUTICS : to Present at the Rodman & Renshaw 16th Annual Global..
09/03 PFIZER : FDA Approves Pediatric Indication for Elelyso (taliglucerase alfa)
08/29 PFIZER : and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indicat..
08/29 PROTALIX BIOTHERAPEUTICS : Other Events, Financial Statements and Exhibits (form..
08/28 PROTALIX BIOTHERAPEUTICS : Announces Conference Call to Discuss ELELYSO Pediatri..
07/24 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
07/24 PROTALIX BIOTHERAPEUTICS : Names Shlomo Yanai as Chairman of the Board of Direct..
06/27 PROTALIX BIOTHERAPEUTICS : Regulation FD Disclosure (form 8-K)
06/27 PROTALIX BIOTHERAPEUTICS : Announces New Data on ELELYSO(TM) (taliglucerase alfa..
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF